Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
Titel:
Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
Auteur:
Hakenberg, Oliver W. Perez-Gracia, Jose Luis Castellano, Daniel Demkow, Tomasz Ali, Tarek Caffo, Orazio Heidenreich, Axel Schultze-Seemann, Wolfgang Sautois, Brieuc Pavlik, Ivan Qin, Amy Novosiadly, Ruslan D. Shahir, Ashwin Ilaria Jr., Robert Nippgen, Johannes